(LNTH) Lantheus Holdings, Inc. Marketing Mix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(LNTH) Lantheus Holdings, Inc. Complete Analysis Pack
Unlock Strategic Clarity
This Lantheus Holdings, Inc. 4P's Marketing Mix Analysis shows what the company sells, how it prices and distributes products, and how it promotes them; use it for marketing research, strategy, or presentations. The page includes a real preview/sample of the analysis so you can review style and content — purchase the full version to get the complete ready-to-use report.
Product
DEFINITY cardiac contrast agent
DEFINITY is Lantheus Holdings, Inc.’s ultrasound contrast agent for cardiac imaging, and it helps improve left ventricular opacification and endocardial border definition during echocardiography. It remains a core branded diagnostic product in the portfolio and supports repeat hospital use in hard-to-see scans. Lantheus reported full-year 2025 revenue of $1.5B, underscoring DEFINITY’s role in the mix.
PYLARIFY PSMA PET imaging
PYLARIFY is Lantheus Holdings, Inc.'s PSMA PET tracer for recurrent or metastatic prostate cancer, helping physicians see lymph nodes, bone, and soft-tissue spread on PET scans. It is the company’s main oncology growth engine; Lantheus reported full-year 2024 PYLARIFY revenue of about $800 million, with demand tied to rising PSMA PET adoption.
TechneLite technetium generator
TechneLite supplies technetium-99m, the workhorse isotope used in about 40 million nuclear medicine procedures a year, and its 6-hour half-life makes generator supply critical for daily hospital use. It supports broad diagnostic imaging in hospitals and imaging centers, from bone and cardiac scans to renal studies. For Lantheus Holdings, Inc., TechneLite is a core isotope supply asset that helps anchor recurring demand in the radiopharmaceutical mix.
AZEDRA and RELISTOR therapies
AZEDRA is a targeted radiopharmaceutical, and RELISTOR treats opioid-induced constipation, so Lantheus gets exposure to both therapy and supportive care. That mix expands the portfolio beyond diagnostics and helps diversify revenue across imaging and treatment uses. In FY2024, Lantheus reported about $1.5 billion in revenue, with non-diagnostic products adding a wider commercial base.
- AZEDRA: targeted therapy
- RELISTOR: constipation care
- Broader revenue mix
Pipeline flurpiridaz F 18 and PYLARIFY AI
Lantheus’ pipeline adds growth beyond its core imaging franchise: flurpiridaz F 18 targets cardiology, while PYLARIFY AI extends prostate cancer imaging with advanced image analysis. Together with 1095, LMI 1195, and leronlimab, the pipeline spans multiple high-value areas and helps diversify revenue beyond current commercial assets.
- Flurpiridaz F 18: cardiology
- PYLARIFY AI: image analysis
- 1095 and LMI 1195: pipeline depth
- Leronlimab: added expansion option
Lantheus Revenue Rests on DEFINITY, PYLARIFY, and TechneLite
Product is centered on DEFINITY, PYLARIFY, and TechneLite, with AZEDRA, RELISTOR, and pipeline assets broadening reach. DEFINITY supports repeat hospital imaging, PYLARIFY drives oncology growth, and TechneLite anchors recurring isotope demand. Lantheus Holdings, Inc. reported 2025 revenue of $1.5B, showing the mix still leans on these core brands.
| Product | Role | FY |
|---|---|---|
| DEFINITY | Cardiac imaging | 2025 |
| PYLARIFY | Prostate cancer PET | 2024 |
| TechneLite | Isotope supply | 2025 |
What is included in the product
Detailed Word Document
A concise, company-specific breakdown of Lantheus Holdings, Inc.’s Product, Price, Place, and Promotion strategy with real-world positioning and competitive context.
Editable Excel File
Simplifies Lantheus Holdings’ 4Ps into a quick snapshot that eases strategy review and stakeholder alignment.
Reference Sources
Provides a concise bibliography tying each Lantheus Holdings claim to primary industry reports, SEC filings, and trusted datasets for fast, defensible due diligence.
Place
Radiopharmacies and distributors
Lantheus uses radiopharmacies and distributors as key channel partners to move time-sensitive radiopharmaceuticals into clinics fast. This matters because fluorine-18 has a 110-minute half-life, so delays can cut usable dose and margin. The model fits products like PYLARIFY, where specialized handling and same-day delivery support clinical access and sales velocity.
Hospitals and clinics
Hospitals and clinics are Lantheus Holdings, Inc.'s main end users because they run cardiac, oncology, and nuclear medicine imaging every day. Products like PYLARIFY and DEFINITY fit high-volume workflows, so the place strategy is to win placements inside busy care centers where scan volume and repeat use matter most. This channel also supports broad access, since U.S. hospital outpatient and clinic settings handle a large share of advanced diagnostic imaging.
Integrated delivery networks
Integrated delivery networks are a key institutional channel for Lantheus Holdings, Inc. because they centralize buying and standardize care across many sites. That gives one contract reach into dozens of hospitals and clinics, so adoption can scale fast and stick longer. In 2024, Lantheus reported $1.4 billion in revenue, and IDN wins can support that base by locking in access.
Group medical practices
Group medical practices are a key access point for Lantheus Holdings, Inc. imaging products because they run outpatient diagnostics and need steady, reliable supply. In FY2024, Lantheus reported $1.53 billion in revenue, showing the scale behind its recurring-use channel model.
That matters in specialized care sites, where repeat scans and predictable ordering support products like PYLARIFY and DEFINITY. The channel helps Lantheus keep usage consistent across smaller, high-throughput practices.
- Outpatient demand supports repeat orders
- Supply reliability drives practice loyalty
- Recurring use fits specialized care sites
Global commercialization partnerships
Lantheus relies on global commercialization partnerships with Bayer, GE Healthcare, Curium, ROTOP, and FUJIFILM to widen access and support local manufacturing or distribution in select markets. This partner-led model helps Lantheus extend reach without building full owned sales networks in every geography.
In FY2024, Lantheus reported net revenue of $1.53 billion, showing how partner channels sit inside a scaled commercial engine. One line: partnerships are the core of Lantheus’s global place strategy.
- Expands reach in key geographies
- Supports local manufacturing and distribution
- Reduces need for owned infrastructure
Fast-Track Distribution Powers Lantheus’s Imaging Reach
Lantheus’s place strategy depends on radiopharmacies, distributors, hospitals, IDNs, and group practices, because its imaging products must move fast and land inside high-volume care sites.
Same-day delivery matters for fluorine-18 products, since its 110-minute half-life limits delay.
Global partners like Bayer and GE Healthcare widen access and support local distribution.
| Channel | Why it matters |
|---|---|
| Radiopharmacies | Fast delivery |
| Hospitals/IDNs | High scan volume |
| Partners | Global reach |
Full Version Awaits
Lantheus Holdings, Inc. Reference Sources
The preview shown here is the exact, full Lantheus Holdings, Inc. 4P’s Marketing Mix analysis you’ll receive instantly after purchase—no sample or demo, fully actionable and ready to use.
It covers product positioning, pricing strategy, placement channels, and promotional tactics with concise insights and recommendations tailored to Lantheus’s diagnostics and imaging portfolio.
This is the same editable, high-quality document included with your order—download immediately and apply the findings to strategy or investor materials.
Promotion
Physician education
Lantheus uses physician education to train imaging specialists on diagnosis, workflow, and patient impact, which matters in tightly regulated radiopharmaceutical markets. Its message is built around better scan accuracy and faster clinical decisions, not just product features. That fits a business that has scaled to more than $1 billion in annual sales, where trust and adoption depend on clinical proof.
Medical congress presence
Lantheus uses medical congresses and scientific meetings to show clinical data for cardiology, oncology, and nuclear medicine, which helps drive awareness and trial use. That matters because the Company reported $1.4 billion in revenue in 2024, so even small uptake gains can move sales. Congress presence also supports launch momentum for pipeline assets by reaching the physicians who shape adoption.
Specialty sales force
Lantheus uses a specialty sales force, not consumer ads, because its buyers are hospitals, IDNs, and radiopharmacies. In FY2025, its commercial model supported account-level education and contracting across a high-value B2B base, with revenue near $1.5B. That fits a market where one IDN decision can affect many sites of care.
Strategic partnership publicity
Lantheus Holdings, Inc. uses strategic partnership publicity to add third-party proof to its platform. Five named alliances, NanoMab, Bausch Health, Regeneron, CytoDyn, and POINT Biopharma, help signal pipeline breadth and commercial reach. That matters in a market where credibility can move faster than product detail.
- Five partner names lift trust
- Signals broader pipeline depth
- Supports commercial scale claims
Disease awareness and access support
Lantheus Holdings, Inc. uses promotion to build disease-state awareness in prostate cancer and cardiovascular care, then pairs it with access support so clinicians can handle reimbursement, ordering, and workflow steps with less friction.
This matters because adoption depends on both institutional approval and payer coverage, especially for imaging products sold into hospital and outpatient settings.
- Disease awareness drives diagnosis and referral
- Access support lowers reimbursement barriers
- Workflow help speeds institutional use
Lantheus Growth Hinges on Education, Access, and Partner Trust
Lantheus promotion leans on physician education, congress data, and specialty sales, with access support that helps hospitals and IDNs adopt imaging products. In FY2025, revenue was about $1.5B, up from $1.4B in 2024, so small adoption gains matter. Five partner names also add trust and pipeline reach.
| Metric | Value |
|---|---|
| FY2025 revenue | About $1.5B |
| FY2024 revenue | $1.4B |
| Named alliances | 5 |
Price
Reimbursement-based pricing
Lantheus Holdings, Inc. sells mostly in reimbursement-driven markets, so realized price depends on payer coverage, coding, and site-of-care rules. This is standard for diagnostic imaging and radiopharmaceuticals like PYLARIFY, where access and net price can shift with Medicare and commercial reimbursement. Lantheus reported $1.33 billion in net revenue in 2024, underscoring how pricing is tied to payer-backed volume, not just list price.
Hospital contract pricing
Hospital contract pricing is negotiated with hospitals, IDNs, and other institutional buyers, so the net price depends on volume, utilization, and service terms. For Lantheus Holdings, Inc., that makes pricing more customized than consumer-style list pricing. In 2025, this model matters because one institutional contract can cover many sites of care and shape unit economics fast.
Specialty premium pricing
Lantheus Holdings, Inc. uses specialty premium pricing because its portfolio serves high-acuity care with diagnostics and therapies that influence fast clinical decisions. In its latest annual period, the Company generated about $1.5 billion in revenue, which shows demand for products tied to diagnostic accuracy and workflow speed. Value comes from clinical impact, not commodity cost.
Formulary and volume discounts
Lantheus Holdings, Inc. can use formulary access and volume commitments to lower net realized price, especially when large health systems negotiate tied utilization and supply agreements. That trade-off can secure preferred channel placement and keep demand steady across institutional accounts. In practice, the price cut is often offset by better volume visibility and stickier access.
- Access deals can reduce unit price.
- Volume commitments support demand planning.
- Preferred formulary placement helps retention.
No public consumer list price
Lantheus Holdings, Inc. does not use a consumer retail price list. Its products move through hospitals, imaging centers, distributors, and payer contracts, so the visible sticker price is rare and net pricing depends on rebates, tenders, and reimbursement terms.
- Institutional sales, not retail checkout
- Net price set by payer contracts
- Distributor and rebate terms matter
- Public list prices are limited
Lantheus Pricing: Reimbursement Drives Revenue, Not Sticker Price
Lantheus Holdings, Inc. uses premium, reimbursement-led pricing: net price is shaped by Medicare, commercial coverage, and hospital contracts, not retail lists. That matters because FY2024 revenue was $1.33 billion, and value comes from access, volume, and formulary wins more than sticker price.
| Price driver | Impact |
|---|---|
| Reimbursement | Sets net realized price |
| Institutional contracts | Volume-linked discounts |
| Formulary access | Improves stickiness |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.